Mateon Therapeutics to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York on September 12, 2016
September 07, 2016 08:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the...
Mateon Provides Corporate Update and Reports Second Quarter 2016 Financial Results
August 03, 2016 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer
July 21, 2016 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
Mateon Announces Initiation of FOCUS Study in Platinum-Resistant Ovarian Cancer
June 23, 2016 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment...
UPDATE -- Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event
June 20, 2016 11:00 ET
|
Mateon Therapeutics
Updated data shows improvement in overall survival of 3.2 months for all CA4P-treated patients Improvement in overall survival is 5.6 months for CA4P-treated patients with measurable disease SOUTH...
Mateon Therapeutics to Present New Improved Survival Outcomes for CA4P in Recurrent Ovarian Cancer at June 27 Investor Event
June 20, 2016 07:15 ET
|
Mateon Therapeutics
Updated data shows improvement in overall survival of 3.2 months for all CA4P-treated patients Improvement in overall survival is 5.6 months for CA4P-treated patients with measurable disease SOUTH...
OXiGENE Announces Name Change to Mateon Therapeutics
June 17, 2016 10:15 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for orphan oncology...
OXiGENE Receives U.S. Orphan Drug Designation for CA4P to Treat Glioma
June 10, 2016 08:30 ET
|
OXiGENE, Inc.
SOUTH SAN FRANCISCO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan...
OXiGENE Announces Results of Phase 2 Study of CA4P in Recurrent Ovarian Cancer Published in Journal of Clinical Oncology
May 24, 2016 06:30 ET
|
Mateon Therapeutics
Study met primary endpoint of improvement in progression free survival Preliminary data show improvement in overall survival of 2.6 months SOUTH SAN FRANCISCO, Calif., May 24, 2016 (GLOBE...
OXiGENE Reports First Quarter 2016 Financial Results
May 09, 2016 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan...